Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
复制标题
DOI：
10.1215/15228517-2008-004
复制
发表时间：
2008-06-01
期刊：
影响因子：
15.9
通讯作者：
Kun, Larry E.
中科院分区：
文献类型：
--
作者：
Haas-Kogan, Daphne A.;Banerjee, Anuradha;Kun, Larry E.
本研究的目的是估计最大耐受剂量（MTD），描述法尼基转移酶（FTase）抑制剂替法尼布（tipifarnib）与放射治疗同时应用于新诊断的弥漫性脑干胶质瘤（BSG）儿童的毒性和初步临床效果。儿童>= 3和
The purpose of this study is to estimate the maximum-tolerated dose (MTD) and describe toxicities and preliminary clinical effects of tipifarnib, a farnesyltransferase (FTase) inhibitor, administered concurrently with radiation therapy in children with newly diagnosed intrinsic diffuse brainstem glioma (BSG). Children >= 3 and